Form 4: BMY Exec's RSU Vesting and Tax-Related Sale

Karin Shanahan, EVP at Bristol-Myers Squibb, saw restricted stock units vest and sold shares to cover tax obligations.

Summary

• Karin Shanahan, Executive Vice President, Chief Supply Chain & Operations at Bristol-Myers Squibb Company, had 6,281 restricted stock units (RSUs) vest on November 1, 2025.
• These RSUs convert into one share of common stock upon vesting.
• Following the vesting, 3,213 shares of common stock were withheld for the payment of taxes at a price of $46.07 per share.
• After these transactions, Shanahan directly beneficially owns 16,865 shares of common stock.
• She also indirectly beneficially owns 1,278.692 shares through the BMS Savings and Investment Program.
• The vesting on November 1, 2025, represents one-third of the restricted stock units granted on November 1, 2024.
• An additional 12,562 restricted stock units remain beneficially owned, which are scheduled to vest in two more equal annual installments.

Sentiment

Score: 7

Explanation: This filing details a routine executive compensation event involving RSU vesting and a tax-related share sale. It is a neutral to slightly positive indicator, reflecting standard executive incentive structures and the executive's realization of earned compensation, without implying any significant operational or strategic changes for the company.

Positives

• The vesting of restricted stock units represents the realization of compensation for the executive, aligning their interests with shareholders.
• The transaction was made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged and systematic approach to equity transactions.

Negatives

• A portion of the vested shares (3,213 shares) was sold to cover tax obligations, resulting in a reduction of direct beneficial ownership.

Future Outlook

The remaining 12,562 restricted stock units beneficially owned by Karin Shanahan are scheduled to vest in two equal annual installments, continuing the executive's equity compensation realization.

Industry Context

The vesting of restricted stock units and subsequent tax-related share sales are standard practices in executive compensation across the pharmaceutical industry. This type of transaction reflects a common mechanism for incentivizing and retaining key executives by aligning their long-term interests with company performance.

Comparison to Industry Standards

• Bristol-Myers Squibb's use of Restricted Stock Units (RSUs) as a component of executive compensation is consistent with practices observed at major pharmaceutical companies such as Pfizer, Merck, and Johnson & Johnson.
• The tax-related sale of shares upon RSU vesting is a routine and expected event, mirroring similar compensation structures and tax compliance mechanisms seen across the S&P 500 and particularly within the healthcare sector.

Stakeholder Impact

• Shareholders: The vesting of RSUs represents a minor, pre-planned dilution event, which is a standard component of executive compensation and generally not material to overall share value.
• Executive (Karin Shanahan): Realization of a portion of her long-term incentive compensation, enhancing personal wealth and aligning her financial interests with the company's performance.

Next Steps

• The remaining 12,562 restricted stock units will vest in two equal annual installments.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are standard practice and do not provide new information regarding Bristol-Myers Squibb's operational performance, strategic direction, or financial health. Therefore, it does not warrant a change in the fundamental investment thesis or recommendation for the stock.

Keywords

Bristol-Myers Squibb, BMY, Form 4, Insider Transaction, RSU Vesting, Executive Compensation, Stock Sale, Karin Shanahan, Equity